Anti-Helicobacter pylori concept stocks are crazy daily limit! Rubbing hot spots? Food and drug administration anti-counterfeiting
Zhongxin Finance, January 8 (Reporter Zhang Ni) Recently, the US Department of Health and Human Services released the 15th edition of the carcinogen report, in which 8 carcinogens were added, and chronic infection of Helicobacter pylori was listed as a definite carcinogen. The news drove the A-share "anti-Helicobacter pylori concept stocks" to set off a wave of daily limit, and the approval of "consumer self-test" products also attracted the attention of the outside world.
Helicobacter pylori is listed as a "clear carcinogen", and the infection rate of Chinese people is more than half.
Helicobacter pylori is a kind of micro-aerobic gram-negative bacilli, which can be spread by sharing chopsticks, sharing toothbrushes and even kissing. It is a bacterium that can colonize human stomach for a long time and cause chronic inflammation.
According to the conservative estimate of the World Gastroenterology Organization (WGO), at least half of the world’s population is infected with Helicobacter pylori. China is the country with the largest number of people infected with Helicobacter pylori, with an infection rate as high as 59%.
"Helicobacter pylori is the main risk factor of gastritis, peptic ulcer and gastric malignant tumor, and may also be related to anemia, thrombocytopenia, diabetes and other diseases." Chen Ning, deputy director of the Department of Gastroenterology, Peking University People’s Hospital, told the reporter of Zhongxin Finance and Economics.
Judging from the incidence of gastric cancer in China in recent years, this can also be confirmed.
The Report on Nutrition and Chronic Diseases of China Residents (2020) released in December 2020 shows that the top five cancer deaths are lung cancer, liver cancer, gastric cancer, esophageal cancer and colorectal cancer.
According to the fifth national consensus report on treatment of Helicobacter pylori infection, about 15%-20% of patients with Helicobacter pylori infection in China have peptic ulcer, 5%-10% have dyspepsia, and about 1% have gastric malignant tumor. Almost all patients with Helicobacter pylori positive have chronic active gastritis.
"Helicobacter pylori is very stubborn. Once infected, the self-healing rate is close to zero unless a formal treatment plan is used. There is a problem with the gastroscope, a family history of gastric cancer, and peptic ulcer. Helicobacter pylori must be eradicated. "
Chen Ning said that for patients who have undergone stomach surgery, have stomach discomfort, or have had stomach cancer in their first-degree relatives, it is recommended to check for Helicobacter pylori.
Its diagnostic methods include traumatic and non-traumatic types. The former depends on gastroscopy biopsy, including rapid urease test, staining microscopy of gastric mucosa tissue sections, bacterial culture, etc. Non-invasive detection methods include 13C or 14C breath test and serum antibody detection.
Therapeutic drugs for Helicobacter pylori sold on an e-commerce platform.
Listed companies "rub" hot spots, and some toothpaste claims that "anti-seclusion" has been counterfeited by the Food and Drug Administration.
"Helicobacter pylori is listed as a clear carcinogen by the United States" has also led to a wave of A-share "anti-Helicobacter pylori concept stocks", and many listed companies have begun to "rub" Helicobacter pylori hotspots, and businesses have speculated on "anti-quiet toothpaste".
On the 5th, SDIC Zhonglu said on the investor interaction platform SSE E that anti-Helicobacter pylori related products are still in the research and development stage, and there are certain uncertainties in the commercial prospects, reminding investors to pay attention to investment risks.
On the 6th, Wise Medicine introduced the interactive platform of investors. The company’s fructooligosaccharides and galactooligosaccharides are typical high-quality prebiotics. At present, foreign studies show that prebiotics can assist in the clearance of Helicobacter pylori drugs to improve the clearance rate. However, the company has not conducted relevant research, and it is impossible to confirm whether it can cooperate with drugs to treat Helicobacter pylori.
Junyao Health recently announced that the company’s main business is still lactic acid bacteria drinks, and the company’s chewable tablets, drinks and other products related to Helicobacter pylori are still in the product investment stage.
In addition, the reporter noticed that some merchants have recently speculated that "anti-secret toothpaste" can kill Helicobacter pylori and prevent gastric cancer, and sell the so-called "anti-secret toothpaste" on the e-commerce platform.
However, on the 7th, National Medical Products Administration issued a response saying that toothpaste claimed that "anti-Helicobacter pylori" lacked scientific basis. Products such as toothpaste claiming to be "anti-Helicobacter pylori" may be added with broad-spectrum bacteriostatic agents. If a large number of broad-spectrum bacteriostats are used for a long time, it may lead to the disorder of oral flora, which is not conducive to oral health.
Screenshot of National Medical Products Administration official website
Enterprises push testing products, can Helicobacter pylori test itself at home in the future?
Just recently, the approval of a Helicobacter pylori testing product has also attracted great attention from the outside world.
A few days ago, Nuohui Health announced that its Helicobacter pylori detection product has become the first Helicobacter pylori detection product approved by National Medical Products Administration for "consumer self-test" in China. Prior to this, the products approved for Helicobacter pylori testing were limited to professional medical personnel in medical units.
According to the company, this product uses double antibody sandwich method to detect whether there is Helicobacter pylori antigen in stool samples. The product realizes the "pregnancy test stick" integrated design of sampling and testing. The user’s operation is simple, painless and non-invasive. There is no need to take medicine before testing, no need for fasting during testing, and no special requirements for sample collection. After sampling, insert the sampling stick back into the reagent tube, shake it evenly for 10 seconds, and press the tube cover for 10 minutes to read the results.
In terms of detection accuracy, the enterprise revealed that the registered clinical trials in three tertiary clinical hospitals in sir run run shaw hospital, Zhejiang People’s Hospital and Peking University Shougang Hospital included 1,644 effective subjects suspected of Helicobacter pylori infection, with a sensitivity of 96.5% and a specificity of 99.1%. Compared with the professional detection results, the coincidence rate reached 100%.
Affected by this news, on January 7, Nuohui Health’s share price once rose by over 40%. (End)